Drugs in Phase II clinical trials for the treatment of age-related macular degeneration (Q38253067)

1 September 2017

1 reference

title

Drugs in Phase II clinical trials for the treatment of age-related macular degeneration (English)

1 reference

1 September 2017

phase II clinical trial

0 references

author name string

Michael John Tolentino

1

1 reference

1 September 2017

Abrahan Dennrick

2

1 reference

1 September 2017

Elizabeth John

3

1 reference

1 September 2017

Michael Steven Tolentino

4

1 reference

1 September 2017

language of work or name

English

0 references

publication date

22 September 2014

1 reference

Expert Opinion on Investigational Drugs

1 September 2017

1 reference

1 September 2017

24

1 reference

1 September 2017

2

1 reference

1 September 2017

183-199

1 reference

Prevalence of age-related macular degeneration in the United States

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Do blue light filters confer protection against age-related macular degeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

The long-term effects of visible light on the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

The role of inflammation and infection in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

A role for local inflammation in the formation of drusen in the aging eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Vascular endothelial growth factor a in intraocular vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Complement factor H polymorphism and age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Complement factor H variant increases the risk of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Complement factor H polymorphism in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunhistochemical analysis of AMD associated with basal deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Drusen proteome analysis: an approach to the etiology of age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Factor H family proteins and human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Associations of CFHR1-CFHR3 deletion and a CFH SNP to age-related macular degeneration are not independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

A2E: a component of ocular lipofuscin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Use of fundus autofluorescence images to predict geographic atrophy progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Photocytotoxicity of lipofuscin in human retinal pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

The age lipid A2E and mitochondrial dysfunction synergistically impair phagocytosis by retinal pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Early changes in gene expression induced by blue light irradiation of A2E-laden retinal pigment epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Current molecular understanding and future treatment strategies for pathologic ocular neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

High-affinity binders selected from designed ankyrin repeat protein libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

DARPins: a new generation of protein therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Nucleic acid aptamers as high affinity ligands in biotechnology and biosensorics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Aptamers in research and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Inhibition of oxygen-induced retinopathy in RTP801-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Knocking down barriers: advances in siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Macrophage polarization in the maculae of age-related macular degeneration: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Host responses in tissue repair and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Microplasmin: ex vivo characterization of its activity in porcine vitreous.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Posterior vitreous detachment induced by microplasmin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Ocriplasmin for vitreoretinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Structural biology of the alternative pathway convertase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Genetic control of the alternative pathway of complement in humans and age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Complement factor D in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Inhibiting Alternative Pathway Complement Activation by Targeting the Factor D Exosite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Drusen complement components C3a and C5a promote choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

The complement component 5 gene and age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

New approaches and potential treatments for dry age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

The role of extrahepatic retinol binding protein in the mobilization of retinoid stores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Studies on the singlet oxygen scavenging mechanism of human macular pigment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Central Retinal Enrichment Supplementation Trials (CREST): design and methodology of the CREST randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

Studies on meso-zeaxanthin for potential toxicity and mutagenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.961601

10.1517/13543784.2015.961601

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference